Clinical guidelines for cryosupernatant transfusions-Reference-Cited by-同舟云学术

Clinical guidelines for cryosupernatant transfusions

Published:2020-09-21 Issue:3 Volume:65 Page:351-359
ISSN:2411-3042
Container-title:Russian journal of hematology and transfusiology
language:
Short-container-title:Gematologiâ i transfuziologiâ

Author:

Galstyan G. M.¹^ORCID,Gaponova T. V.¹^ORCID,Sherstnev F. S.²^ORCID,Kupryashov A. A.³^ORCID,Olovnikova N. I.¹^ORCID,Zozulya N. I.¹^ORCID,Troitskaya V. V.¹^ORCID,Mazurok V. A.⁴^ORCID,Pevtcov D. E.⁵^ORCID,Salimov E. L.⁶^ORCID,Trakhtman P. E.⁷^ORCID,Savchenko V. G.¹^ORCID

Affiliation:

1. National Research Center for Hematology

2. Kirov Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency of Russia

3. A.N. Bakulev National Medical Research Center of Cardiovascular Surgery

4. Almazov National Medical Research Centre

5. I.P. Pavlov First Saint Petersburg State Medical University

6. I.M. Sechenov First Moscow State Medical University

7. Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology

Abstract

Introduction. Cryosupernatant is blood component. Cryosupernatant is the supernatant plasma removed during the preparation of cryoprecipitate. Aim. To provide information on the composition and methods of production, storage, transportation and clinical use of Cryosupernatant. General fi ndings. In comparison with fresh frozen plasma (FFP) and cryoprecipitate, Cryosupernatant plasma is depleted in factor VIII, fi brinogen factor von Willebrand (VWF). Cryosupernatant is defi cient in high molecular weight multimers of VWF, but contains VWF metalloproteinase. The concentrations of factor V, antithrombin III, albumin and immunoglobulins are the same as in FFP and cryoprecipitate. The indications for Cryosupernatant transfusions are massive blood loss in patients with factor VIII inhibitor, plasma exchange in patients with thrombotic thrombocytopenic purpura. For children the doses of Cryosupernatant should be 10-15 mL/kg.

Publisher

National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation

Subject

Hematology

Reference18 articles.

1. Freedman M., Rock G. Analysis of the products of cryoprecipitation: RiCoF is defi cient in cryosupernatant plasma. Transfusion and Apheresis Science. 2010; 43(2): 179–82. DOI: 10.1016/j.transci.2010.07.004.

2. Hori Y., Hayakawa M., Isonishi A. et al. ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: Implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment. Transfusion. 2013; 53(12): 3192–202. DOI: 10.1111/trf.12182.

3. Raife T.J., Friedman K.D., Dwyre D.M. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma Thomas. Transfusion. 2006; 46: 74–9. DOI: 10.1111/j.1537- 2995.2006.00674.x.

4. RАТ. Donor blood and its components: characteristics and quality control. XIV. Cryosupernatant plasma. 2005 (In Russian).

5. Canadian Blood Service. Circular of information. For the use of human blood components. 2018.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of thrombotic thrombocytopenic purpura;Terapevticheskii arkhiv;2021-07-23